Optimizing the management of atrial fibrillation

Focus on current guidelines and the impact of new agents on future recommendations

Gerald Naccarelli, Anne B. Curtis

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in everyday clinical practice. It affects ∼2.3 million individuals in the United States, and the prevalence is expected to increase ∼2.5-fold over the next 40 years. Atrial fibrillation accounts for more than 2 million hospitalizations each year and contributes to nearly 67 000 deaths. Our understanding of the pathophysiology of AF has increased dramatically over the past few decades. Recent treatment guidelines have heightened our awareness of the challenges involved in the treatment of AF and provided useful recommendations for its diagnosis and management. Because AF is usually associated with multiple comorbid conditions, greater emphasis must be placed on individualizing treatment. This review focuses on current treatment guidelines for patients with AF, assessing the benefits and shortcomings of current pharmacologic options and discussing new agents and trials that may provide better opportunities to improve and individualize patient management.

Original languageEnglish (US)
Pages (from-to)244-256
Number of pages13
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume15
Issue number3
DOIs
StatePublished - Sep 1 2010

Fingerprint

Atrial Fibrillation
Guidelines
Therapeutics
Cardiac Arrhythmias
Hospitalization

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{058579cd02e34de395215145799e0a23,
title = "Optimizing the management of atrial fibrillation: Focus on current guidelines and the impact of new agents on future recommendations",
abstract = "Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in everyday clinical practice. It affects ∼2.3 million individuals in the United States, and the prevalence is expected to increase ∼2.5-fold over the next 40 years. Atrial fibrillation accounts for more than 2 million hospitalizations each year and contributes to nearly 67 000 deaths. Our understanding of the pathophysiology of AF has increased dramatically over the past few decades. Recent treatment guidelines have heightened our awareness of the challenges involved in the treatment of AF and provided useful recommendations for its diagnosis and management. Because AF is usually associated with multiple comorbid conditions, greater emphasis must be placed on individualizing treatment. This review focuses on current treatment guidelines for patients with AF, assessing the benefits and shortcomings of current pharmacologic options and discussing new agents and trials that may provide better opportunities to improve and individualize patient management.",
author = "Gerald Naccarelli and Curtis, {Anne B.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1177/1074248410370964",
language = "English (US)",
volume = "15",
pages = "244--256",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Optimizing the management of atrial fibrillation

T2 - Focus on current guidelines and the impact of new agents on future recommendations

AU - Naccarelli, Gerald

AU - Curtis, Anne B.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in everyday clinical practice. It affects ∼2.3 million individuals in the United States, and the prevalence is expected to increase ∼2.5-fold over the next 40 years. Atrial fibrillation accounts for more than 2 million hospitalizations each year and contributes to nearly 67 000 deaths. Our understanding of the pathophysiology of AF has increased dramatically over the past few decades. Recent treatment guidelines have heightened our awareness of the challenges involved in the treatment of AF and provided useful recommendations for its diagnosis and management. Because AF is usually associated with multiple comorbid conditions, greater emphasis must be placed on individualizing treatment. This review focuses on current treatment guidelines for patients with AF, assessing the benefits and shortcomings of current pharmacologic options and discussing new agents and trials that may provide better opportunities to improve and individualize patient management.

AB - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in everyday clinical practice. It affects ∼2.3 million individuals in the United States, and the prevalence is expected to increase ∼2.5-fold over the next 40 years. Atrial fibrillation accounts for more than 2 million hospitalizations each year and contributes to nearly 67 000 deaths. Our understanding of the pathophysiology of AF has increased dramatically over the past few decades. Recent treatment guidelines have heightened our awareness of the challenges involved in the treatment of AF and provided useful recommendations for its diagnosis and management. Because AF is usually associated with multiple comorbid conditions, greater emphasis must be placed on individualizing treatment. This review focuses on current treatment guidelines for patients with AF, assessing the benefits and shortcomings of current pharmacologic options and discussing new agents and trials that may provide better opportunities to improve and individualize patient management.

UR - http://www.scopus.com/inward/record.url?scp=77956800125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956800125&partnerID=8YFLogxK

U2 - 10.1177/1074248410370964

DO - 10.1177/1074248410370964

M3 - Review article

VL - 15

SP - 244

EP - 256

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 3

ER -